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Abstract Androgens are essential for normal prostate physiol-
ogy and have a permissive role in the development and 
progression of prostate cancer. Using the mRNA differential 
display technique, ornithine decarboxylase (ODC) was identified 
to be up-regulated by androgens in human prostatic LNCaP 
cells. On Northern analysis, the induction of ODC expression by 
10 nlYI androgen was rapid and continued up to 48 h exposure 
with a maximum 6.3-fold up-regulation. The anti-androgen 
Casodex inhibited the androgen-induced up-regulation of ODC, 
whereas the protein synthesis inhibitor cycloheximide did not. 
Together these data suggest that regulation is mediated through 
the androgen receptor protein and does require secondary protein 
synthesis, respectively. The kinetics of induction of ODC were 
almost identical to those of prostate specific antigen. Taken 
together these data suggest that ODC is directly regulated by 
androgens in LNCaP cells. 
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1. Introduction 
In American and European males prostate cancer is the 
second most common cause of cancer-related death, with 
more than 317 000 new cases diagnosed and over 41000 
deaths occurring every year in the U S A [1]. As androgens 
regulate normal growth and differentiation of the prostate, 
androgen regulated genes are likely to contribute to the devel-
opment and progression of prostate cancer. Androgen respon-
sive genes such as prostate specific antigen (PSA) [2] and 
prostate specific membrane antigen [3] have been character-
ized and PSA is commonly used as a clinical marker for pros-
tate cancer [4]. 
Despite the fact that the human prostate is highly androgen 
responsive, few androgen responsive genes have been cloned. 
We have used the differential display (DD) technique [5,6] to 
identify androgen responsive genes in human prostatic cells. 
Using this strategy, ornithine decarboxylase (ODC) was iden-
tified as an androgen responsive gene. Ornithine decarboxy-
lase is the first, rate-controlling enzyme in the polyamine bio-
synthesis pathway and catalyses the conversion of ornithine to 
putrescine. Polyamines are found in high concentrations in the 
prostate and may influence the growth and progression of 
prostate cancer. For instance, levels of the polyamine sper-
mine are elevated in prostatic hyperplasia and spermine may 
inhibit the growth of malignant prostatic cells [7]. In addition, 
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O D C activity is highly responsive to stimuli affecting cell 
growth and differentiation [8,9]. 
Regulation of O D C activity can occur via transcription, 
translation and post-translational mechanisms in a complex 
cell-specific manner. Its m R N A levels are elevated in animal 
tumours, certain transformed cell lines and human tumour 
models in the colon, skin and breast [10]. Disruption of 
O D C function results in the arrest of cell proliferation in 
tissue culture and in animal tumors in vivo [11] and over-
expression of O D C in NIH/3T3 cells gives rise to loss of 
contact inhibition, anchorage independent growth and in-
creased tumourigenesis [12,13]. O D C m R N A levels are up-
regulated 5-10-fold by androgens in the rodent kidney, pros-
tate and accessory sex organs [14], anti-estrogens in the M C F -
7 cell line [15] and the 'Wilms tumour suppressor WT-1 in 
H C T 116, NIH/3T3 and HepG2 cells [16]. 
Characterization of the androgen regulated expression of 
O D C was investigated using the anti-androgen Casodex and 
the protein synthesis inhibitor cycloheximide. These studies 
demonstrated that the androgen-induced up-regulation of 
O D C was mediated through the androgen receptor and was 
independent of secondary protein synthesis. Thus, O D C may 
be an example of a key cellular metabolism gene that is di-
rectly regulated by androgens. 
2. Materials and methods 
2.1. Materials 
LNCaP cells were obtained from the American Type Culture Col-
lection (Rockville, MD), RPMI 1640 from GibcoBRL (Paisley, UK), 
and foetal calf serum (FCS) from Sigma (Poole, UK). Radioisotopes 
were from ICN (Irvine, CA) and enzymes from NBL (Cramlington, 
UK). The synthetic androgen mibolerone was purchased from New 
England Nuclear-DuPont (Stevenage, UK). Casodex was generously 
provided by Zeneca (Macclesfield, UK). All other reagents were from 
Sigma unless otherwise stated. 
2.2. Cell culture 
LNCaP cells (passage 33-38) were routinely maintained in RPMI 
1640 containing L-glutamine (20 mM) and supplemented with 10% 
FCS, Penicillin (100 IU ml"1) and streptomycin (100 ug ml"1). For 
androgen exposures the cells were plated out in complete growth 
medium and allowed to adhere for 24-48 h. Cultures were washed 
twice with phosphate-buffered saline then exposed to RPMI 1640 
medium supplemented with 10% steroid-depleted, dextran-coated 
charcoal-treated FCS (DCC medium) for 72 h. Fresh DCC medium 
was added containing 10 nM mibolerone and the cells were incubated 
at 37°C for periods of up to 48 h. 
2.3. Differential display 
Differential display was performed essentially as described [5], with 
the following modifications. Total RNA was extracted from cells as 
previously described [17]. PolyA+ RNA was purified using Dynabeads 
Oligo (dT2s) according to the manufacturer's protocol (Dynal). For 
each DD reaction, 0.25 ug of polyA+ RNA was reverse transcribed 
using T12VC as a primer and AMV reverse transcriptase (400 U ml"1; 
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Life Sciences). Differential display was performed in duplicate using 
primers T12VC and 1016 (5'-AGCCAGCGAA-3'), [a-
32P]dATP (500 
uCi ml-1) and AmpliTaq DNA polymerase (50 U ml -1; Perkin Elmer 
Cetus). Differential display reactions were subjected to 30 cycles of 
PCR comprising 94°C for 30 s, 40°C for 20 s and 72°C for 30 s. 
Products of the PCR were electrophoresed on 6% non-denaturing 
polyacrylamide gels at 400 V for 20 h. DNA from bands thought to 
be differentially expressed was extracted by elution into 200 JJ.1 of 
water and the cDNA recovered by ethanol precipitation. Eluted 
cDNA species were re-amplified using 15 cycles of PCR with the 
appropriate primers and cloned into the pCRII vector (Invitrogen) 
according to the manufacturer's protocol. The DNA sequences of 
the differential display clones were determined using the Thermo Se-
quenase cycle sequencing kit (Amersham Life Sciences) and homolo-
gies to known genes determined using the Genbank database. 
2.4. Northern blotting 
RNA samples were electrophoresed as previously described [18]. 
Briefly, 5 ug of each RNA was fractionated on agarose gels, trans-
ferred to a nylon membrane (Hybond N+; Amersham), fixed by heat-
ing at 80°C for 2 h and stained with methylene blue to assess the 
integrity of the RNA. Probes were generated from cloned cDNAs by 
restriction endonuclease digestion. The PSA probe was an 805 bp 
cDNA generated from LNCaP RNA using reverse transcriptase-
PCR as previously described [19]. Probes were radiolabelled with 
[o>32P]dATP using random-primed labelling mixture according to 
the manufacturer's protocol (Boehringer-Mannheim). RNA blots 
were hybridized at 65°C to denatured, radiolabelled cDNAs; hybrid-
ization conditions and washing procedures were carried out as previ-
ously described [20]. Blots were analyzed after exposure to a phosphor 
storage screen using a Phosphorimager (Molecular Dynamics). Blots 
were subsequently re-probed with radiolabelled glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA as a control for RNA 
loading. The expression of ODC and PSA was calculated relative to 
GAPDH and untreated control cells (such that untreated cells have a 
relative mRNA expression value of 1). 
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3. Results 
3.1. Identification of ODC as an androgen responsive gene 
Differential display was performed in duplicate on polyA+ 
RNA from untreated LNCaP cells and cells exposed to 10 nM 
mibolerone for 8 or 48 h. A representative result using a single 
primer set is shown in Fig. 1. The band patterns were at least 
90% identical between duplicate samples. However, several 
mRNAs were reproducibly differentially expressed, of which 
one was up-regulated after 8 and 48 h androgen exposure 
when compared to untreated control cells (labelled ODC). 
This band was excised from the gel, cloned into the PCRII 
vector and four clones were fully sequenced (data not shown). 
All four clones contained a 96 bp cDNA insert with the cor-
rect flanking primers (T12VC and 1016). A search of the Gen-
Bank database revealed an 89% homology with the 3' end of 
the human ornithine decarboxylase gene (Fig. 2). The DNA 
alignment included the first 12 bases of the poly A tail and an 
adjacent putative polyadenylation signal. 
O D C * 
3.2. Temporal changes in ODC mRNA levels in response to 
androgen 
To confirm the putative androgen regulated expression of 
ODC and to determine the temporal pattern of ODC induc-
tion, LNCaP cells were treated with 10 nM mibolerone for 
varying lengths of time and the levels of ODC assessed using 
Northern analysis. The ODC and PSA probes identified spe-
cies of 2.3 and 1.6 kb, respectively, as previously reported 
[2,21]. ODC and PSA were up-regulated between 4 and 48 h 
exposure to mibolerone to a maximum of 6.3- and 5.1-fold, 
respectively (Fig. 3). Both genes showed a rapid response to 
Fig. 1. Differential display of mibolerone-treated LNCaP Cells. DD 
was performed, in duplicate, on polyA+ RNA from untreated 
LNCaP cells (lane 1) and cells exposed to 10 nM mibolerone for 8 
(lane 2) or 48 (lane 3) h as described in Section 2. A representative 
experiment carried out in duplicate (marked with primed numbers) 
using primers Ti2VC and 1016 (lanes 1-3) is shown. A closed arrow 
indicates a clone that was subsequently confirmed as differentially 
expressed (ODC). 
androgen treatment, with ODC up-regulated 1.2-fold and 
PSA up-regulated 1.3-fold after 4 h exposure to mibolerone. 
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DD :AGCCAGCGAA CTACCTATTG TAGCTTGTAC 3 0 
ODC: T--T -A-G-AT 7896 
DD :CATGGCAGA ATGGGCCAAAA GCTTAGTGTT 60 
ODC:A 7926 
DD : GTGACCCGTT TTTAAAATAA AGCAAAAAA 90 
ODC: — C T --A 7956 
DD : 
ODC: 
AAAAAA 96 
7962 
Fig. 2. Nucleotide sequence homology of a DD derived clone with 
human ODC. The nucleotide sequence of a DD derived clone and 
homology with the 3' untranslated region of human ODC mRNA 
is shown. Dashes represent identical bases, flanking primer sequen-
ces are in boldface letters (1016 and T12VC), the polyadenylation 
signal is underlined and base numbering correlates with previous 
references [21]. 
ulation of cells relative to another. We have used the DD 
procedure to identify elevated levels of ODC mRNA in re-
sponse to androgen treatment of human prostatic cells. The 
rapid induction of ODC detected using DD was confirmed 
using Northern analysis, indicating that DD can detect tem-
poral changes in gene expression. The kinetics of induction of 
ODC expression by androgens in LNCaP cells were almost 
identical to those of PSA when using Northern analysis [2], 
indicating that ODC is highly androgen responsive. 
The up-regulation of ODC by androgen is mediated via the 
activated androgen receptor as Casodex, a competitive inhib-
itor of the androgen receptor, completely abolishes the mibo-
A) 1 
The kinetics of induction of ODC and PSA were very similar 
and the expression of both genes was decreased when cultured 
in DCC medium alone when compared to cells cultured in 
standard culture medium. This suggests androgen withdrawal 
decreases ODC and PSA expression and that their expression 
may be androgen dependent. 
3.3. The effect of Casodex on ODC expression 
LNCaP cells were exposed to the non-steroidal anti-andro-
gen Casodex [22] for 24 h, followed by addition of 10 nM 
mibolerone, in the presence of Casodex, for a further 12^-8 h. 
The expression of ODC was assessed by Northern analysis. 
There was no significant change in ODC expression when 
mibolerone was added in the presence of Casodex (Fig. 4). 
The abolishment of the mibolerone-induced increase in ODC 
expression by Casodex confirms that this effect is mediated 
through the androgen receptor. Casodex treatment alone did 
not affect ODC expression. 
B) 
3.4. The effect of cycloheximide on ODC expression 
LNCaP cells were exposed to the protein synthesis inhibi-
tor, cycloheximide (Cx) for 1 h before exposure to 10 nM 
mibolerone for between 4 and 48 h. The expression of ODC 
was examined using Northern analysis. The expression of 
ODC was increased between 4 and 8 h exposure to miboler-
one in the presence of Cx (Fig. 5). Interestingly, ODC expres-
sion appeared to be slightly augmented by Cx at these expo-
sures. The expression of ODC reached a maximum of 2.6-fold 
above control levels after 8 h exposure to mibolerone in the 
presence of Cx, compared to a 2.1-fold induction of ODC by 
mibolerone alone (see Fig. 3). Between 8 and 24 h of miboler-
one exposure, ODC expression remained elevated; after 48 h 
exposure, ODC expression fell to 1.6-fold above control lev-
els, suggesting that the mibolerone-induced up-regulation of 
ODC expression is a primary response to androgen and does 
not require de novo protein synthesis. Identical experiments 
were performed examining PSA gene expression as a control. 
The mibolerone-induced up-regulation of PSA expression was 
unaffected by Cx and showed almost identical kinetics of in-
duction to that seen by ODC (data not shown). 
4. Discussion 
Differential display is a powerful technique to identify genes 
that are present/absent or differentially expressed in one pop-
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Fig. 3. Effects of 10 nM mibolerone on ODC and PSA expression. 
Northern analysis was performed using total RNA from untreated 
LNCaP cells (lane 1), cells exposed to 10 nM mibolerone for 4, 8, 
24 and 48 h (lanes 2-5, respectively) and cells exposed to full me-
dium for 48 h (lane 6/FM). (A) Blots were probed with an ODC 
cDNA then stripped and reprobed with a PSA cDNA. Blots were 
again stripped and reprobed with a GAPDH cDNA as a control 
for gel loading. (B) The expression of ODC (hatched bars) and PSA 
(solid bars) was normalised to GAPDH and the expression relative 
to untreated control cells was calculated. 
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lerone-induced up-regulation of ODC. Similar methods were 
used to implicate the androgen receptor in the androgen regu-
lated expression of proliferating cell nuclear antigen [23]. The 
androgen receptor of LNCaP cells has a mutation at amino 
acid 868, which can cause certain anti-androgens to have a 
mildly androgenic effect [22]. However, Casodex is a highly 
specific anti-androgen and does not have any androgenic ef-
fects in LNCaP cells [22]. 
The androgen-induced up-regulation of ODC does not in-
volve de novo protein synthesis, as cycloheximide failed to 
prevent the initial up-regulation of ODC. This suggests that 
ODC is directly regulated by the existing activated androgen 
receptor protein. Similar results have previously been reported 
for PSA [2]. However, ODC mRNA levels were reduced be-
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Fig. 4. Effects of Casodex on the mibolerone-induced expression of 
ODC. Northern analysis was performed using total RNA from un-
treated LNCaP cells (lane 1), cells exposed to 10 uM Casodex for 
24 h (lane 2) and cells exposed to 10 uM Casodex for 24 h followed 
by 10 nM mibolerone for 12, 24, 36 and 48 h (lanes 3-6, respec-
tively). (A) Blots were probed with an ODC cDNA, then stripped 
and reprobed with a GAPDH cDNA as a control for gel loading. 
(B) The expression of ODC was normalised to GAPDH and the ex-
pression relative to Casodex treated control cells (labelled 'C') was 
calculated. 
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Fig. 5. Effects of cycloheximide on ODC expression. Northern anal-
ysis was performed using total RNA from LNCaP cells exposed to 
cycloheximide for 1 h (lane 1) and cells exposed to cycloheximide 
for 1 h followed by 10 nM mibolerone for 4, 8, 24 and 48 h (lanes 
2-5 respectively). (A) Blots were probed with an ODC cDNA then 
stripped and reprobed with a GAPDH cDNA as a control for gel 
loading. (B) The expression of ODC was normalised to GAPDH 
and the expression relative to cycloheximide treated control cells 
was calculated. 
tween 24 and 48 h exposure to mibolerone in the presence of 
cycloheximide. This could be due to either a breakdown in the 
cellular transcription machinery caused by inhibition of pro-
tein synthesis, or degradation of the ODC mRNA by virtue of 
its natural half life. 
The androgen regulated expression of PSA has recently 
been characterized in detail [24,25]. The activated androgen 
receptor can bind to several androgen response elements and 
enhancer regions within the promoter region leading to tran-
scription of the target gene. Thus, the androgenic regulation 
of PSA expression is directly influenced by the activated an-
drogen receptor. However, although the expression of ODC 
has previously been shown to be directly regulated by andro-
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gens in the rodent model system [14], the mechanism of an-
drogen regulation of the human gene has not been elucidated. 
The 5' untranslated region of the human gene contains se-
quences similar to steroid hormone responsive elements [21], 
al though no functional androgen responsive elements have 
been found in the first 8 kb of the gene promoter region 
[26]. This suggests that either an androgen responsive element 
may be further upstream than 8 kb or androgenic regulation 
of O D C may not involve androgen receptor-DNA interaction, 
the latter of which has previously been reported for androgen 
receptor mediated transcriptional regulation [27]. 
The regulation of O D C by androgen has important impli-
cations in the androgenic control of cell growth and may in 
part explain the androgen dependent nature of certain tissues 
and cell lines. Similar genes that are influenced by androgens 
and are involved in cellular proliferation and progression of 
the cell cycle, such as early growth response gene a and pro-
liferating cell nuclear antigen, have been previously reported 
[23,28]. This suggests that androgens may directly influence 
key cellular processes to regulate cell growth and differentia-
tion. Further study into the regulation of O D C in the prostate 
will clearly give interesting insights into the mechanism of 
androgen dependent prostate cell growth. 
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